RTX therapy in patients with EGPA
| Reference | Study design | Number of patients | Dose and route of administration | Results |
|---|---|---|---|---|
| Cartin-Ceba et al. [89], 2011 | Prospective open-label pilot study | 3 | 375 mg/m2 every 4 weeks | All patients achieved renal remission |
| Thiel et al. [85], 2013 | Single-center cohort of patients | 9 | No recorded | CS reductionBVAS reductionC-reactive protein normalizedReduction in blood eosinophil countsNo relapses had been recorded |
| Mohammad et al. [83], 2016 | Cohort of patients | 41 | 375 mg/m2 every 4 weeks (n = 10)2 doses 1,000 mg (n = 30) | 34% Of the patients achieved remissionCS reduction in all patientsANCA-positivity at baseline was associated with a higher remission rate at 12 monthsNo differences in eosinophil counts |
| Teixera et al. [87], 2019 | Cohort of patients | 69 | - | No differences in treatment response according to ANCA-statusCS reductionsNo changes in blood eosinophil counts |
-: blank cell
ACH: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. CP: Conceptualization, Investigation, Visualization, Writing—review & editing. GP: Validation, Writing—review & editing, Supervision. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.